Globalinternet: “Now is the Time to Rethink Your Sourcing Strategy for Network Connectivity”
5.10.2020 15:00:00 EEST | Business Wire | Press release
Globalinternet, the Amsterdam-headquartered company that provides connectivity for more than 600 enterprises globally, today releases a white paper on what they call the ‘Accelerated Internet Shift’. The white paper focuses on the accelerating shift from private to public networks, including the impact of COVID-19 on large corporations that had to rethink their entire operational practices while employees were forced to work from home.
The white paper, commissioned in partnership with research consultancy Omdia, is a comprehensive tool for CIOs and IT executives around the world to get the latest insights regarding internet connectivity during the current pandemic and beyond. It underlines the importance for enterprises to prioritise network transformation projects and so becoming resilient in a post-COVID / Work-from-home world.
The research shows that existing global network service providers are a known quantity but more and more enterprises are looking for new suppliers to source their network services as a way to get fresh perspectives and more competitive solutions. For example: no less than 49% of enterprises turned to new network providers when adopting SD-WAN, and more than one-third of large enterprises expect to re-reconsider their primary network partner.
“The shift from private to public networks was a trend that was on our radar for a long time,” says Kees Bos, CEO Globalinternet. “But the big news is that this is accelerating at a high speed. Enterprises have felt the first shock from COVID and, despite needing to cut budgets for the foreseeable future, these enterprises are prioritizing the shift to internet and SD-WAN. They realize that money spent today on these network enhancements will help the company be nimbler and in a stronger position tomorrow”
The full white paper can be downloaded here.
About Globalinternet
Globalinternet is a leading provider for business-grade internet connectivity – anywhere on the planet. We partner with brilliant local Internet Service Providers and technology partners in 190+ countries to offer a best-in-class product portfolio with an unparalleled range of dedicated, broadband and mobile internet access services, coupled with around-the-clock assurance and support.
Founded in 2012, Globalinternet has worked since with more than 600 enterprises, delivering the underlay to enable their network transformation projects. Customers can monitor and manage their diverse internet services through the GINius customer portal. The portal supports APIs for fully automated integration with enterprises’ internal systems allowing them to take control of their internet underlay. For more information: www.globalinter.net
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005412/en/
Contact information
Press Contacts
Daniela Muente
Head of Global Marketing
Daniela.Muente@Globalinter.net
+31 654355430
Linda Roemer
Marketing Manager
Linda.Roemer@Globalinter.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom